Alliance International Resources

Alliance International Resources is a Hong Kong-based clinical development company and Contract Research Organization (CRO) that specializes in the advancement of novel therapeutics in the Asia-Pacific region. The company acts as a vital link between academic research and commercial drug development, specifically partnering with the State Key Laboratory of Biotherapy (SKLB) in China to sponsor and manage clinical trials for a range of small molecule candidates. Its portfolio primarily focuses on multi-kinase inhibitors for oncology, such as SKLB102 and SKLB610, which target pathways like VEGFR and PDGFR, as well as treatments for autoimmune conditions like rheumatoid arthritis. Alliance International Resources provides full-service clinical solutions including regulatory affairs, trial monitoring, and project management to facilitate drug approvals in the Chinese market. The company plays a significant role in transitioning early-stage biopharmaceutical assets from the laboratory into multi-center clinical studies.